 Franklin Wright
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wounds and Injuries | 16 | 2025 | 711 | 2.350 |
Why?
| | Blood Transfusion | 9 | 2025 | 296 | 1.330 |
Why?
| | Trauma Centers | 5 | 2025 | 402 | 1.270 |
Why?
| | Resuscitation | 6 | 2024 | 237 | 1.140 |
Why?
| | Blood Component Transfusion | 4 | 2025 | 82 | 0.910 |
Why?
| | Venous Thrombosis | 2 | 2025 | 176 | 0.880 |
Why?
| | Hemorrhage | 4 | 2025 | 678 | 0.810 |
Why?
| | Shock, Hemorrhagic | 3 | 2024 | 165 | 0.770 |
Why?
| | Altitude | 1 | 2025 | 461 | 0.700 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 60 | 0.670 |
Why?
| | Trauma Severity Indices | 1 | 2019 | 104 | 0.630 |
Why?
| | Thromboembolism | 1 | 2020 | 112 | 0.630 |
Why?
| | Fibrinolysis | 1 | 2020 | 137 | 0.620 |
Why?
| | Extremities | 1 | 2019 | 127 | 0.610 |
Why?
| | Hypocalcemia | 3 | 2023 | 28 | 0.570 |
Why?
| | Plasma | 1 | 2018 | 206 | 0.540 |
Why?
| | Triage | 1 | 2018 | 206 | 0.520 |
Why?
| | Injury Severity Score | 6 | 2025 | 509 | 0.520 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 341 | 0.480 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.480 |
Why?
| | Quality Improvement | 6 | 2025 | 1101 | 0.420 |
Why?
| | Transfusion Reaction | 2 | 2025 | 43 | 0.420 |
Why?
| | Interleukin-1beta | 1 | 2014 | 372 | 0.400 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 1198 | 0.380 |
Why?
| | Tissue Plasminogen Activator | 2 | 2021 | 222 | 0.330 |
Why?
| | Adult | 22 | 2025 | 35572 | 0.330 |
Why?
| | Retrospective Studies | 13 | 2025 | 14519 | 0.320 |
Why?
| | Middle Aged | 18 | 2025 | 31150 | 0.310 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1418 | 0.300 |
Why?
| | Saline Solution, Hypertonic | 3 | 2014 | 40 | 0.290 |
Why?
| | Registries | 3 | 2024 | 1895 | 0.280 |
Why?
| | ABO Blood-Group System | 2 | 2024 | 39 | 0.280 |
Why?
| | Male | 23 | 2025 | 63674 | 0.250 |
Why?
| | Wounds, Penetrating | 2 | 2019 | 63 | 0.240 |
Why?
| | Female | 21 | 2025 | 68770 | 0.220 |
Why?
| | Airway Management | 1 | 2024 | 44 | 0.220 |
Why?
| | Lung | 2 | 2014 | 3931 | 0.220 |
Why?
| | Vital Signs | 1 | 2024 | 41 | 0.220 |
Why?
| | Thoracostomy | 1 | 2004 | 17 | 0.220 |
Why?
| | Liver Transplantation | 3 | 2024 | 831 | 0.220 |
Why?
| | Partial Thromboplastin Time | 2 | 2021 | 52 | 0.220 |
Why?
| | Inflammation | 1 | 2014 | 2736 | 0.220 |
Why?
| | Propensity Score | 1 | 2025 | 265 | 0.220 |
Why?
| | Hemostatics | 1 | 2004 | 49 | 0.210 |
Why?
| | Humans | 30 | 2025 | 129622 | 0.210 |
Why?
| | Wounds, Gunshot | 2 | 2019 | 213 | 0.200 |
Why?
| | Pandemics | 2 | 2021 | 1486 | 0.200 |
Why?
| | Aged | 14 | 2025 | 22099 | 0.190 |
Why?
| | Intubation, Intratracheal | 1 | 2024 | 239 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 211 | 0.190 |
Why?
| | Advance Directives | 1 | 2022 | 77 | 0.180 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 9 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2024 | 867 | 0.170 |
Why?
| | Venous Thromboembolism | 1 | 2024 | 284 | 0.170 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 82 | 0.160 |
Why?
| | Calcium | 2 | 2023 | 1213 | 0.160 |
Why?
| | Thrombelastography | 1 | 2020 | 150 | 0.160 |
Why?
| | Critical Illness | 2 | 2021 | 758 | 0.150 |
Why?
| | Sepsis | 1 | 2025 | 574 | 0.150 |
Why?
| | NF-kappa B | 2 | 2014 | 653 | 0.150 |
Why?
| | Cerebrovascular Disorders | 1 | 2019 | 90 | 0.150 |
Why?
| | Thrombosis | 1 | 2021 | 343 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 313 | 0.140 |
Why?
| | Emergency Medical Services | 2 | 2024 | 522 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 249 | 0.140 |
Why?
| | Military Personnel | 1 | 2024 | 515 | 0.140 |
Why?
| | Clinical Protocols | 1 | 2018 | 255 | 0.140 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1838 | 0.130 |
Why?
| | Violence | 1 | 2019 | 242 | 0.130 |
Why?
| | Oxygen | 1 | 2021 | 915 | 0.130 |
Why?
| | Risk Factors | 5 | 2025 | 9763 | 0.130 |
Why?
| | Renal Dialysis | 1 | 2020 | 423 | 0.130 |
Why?
| | Epithelial Cells | 2 | 2014 | 1065 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2022 | 7084 | 0.120 |
Why?
| | Intensive Care Units | 1 | 2020 | 738 | 0.120 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 81 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1952 | 0.110 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 1902 | 0.110 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 23 | 0.100 |
Why?
| | Phosphorylation | 2 | 2014 | 1713 | 0.100 |
Why?
| | Cell Line | 2 | 2014 | 2781 | 0.090 |
Why?
| | Young Adult | 6 | 2025 | 12426 | 0.090 |
Why?
| | Colorado | 1 | 2019 | 4420 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2012 | 279 | 0.080 |
Why?
| | Stroke | 1 | 2018 | 1071 | 0.080 |
Why?
| | Survivors | 1 | 2012 | 464 | 0.080 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 20 | 0.080 |
Why?
| | Liver Failure | 1 | 2008 | 91 | 0.070 |
Why?
| | Respiration, Artificial | 2 | 2022 | 613 | 0.070 |
Why?
| | Adolescent | 6 | 2025 | 20391 | 0.060 |
Why?
| | Incidence | 3 | 2022 | 2644 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 522 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2012 | 1022 | 0.060 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2007 | 272 | 0.060 |
Why?
| | United States Department of Defense | 1 | 2024 | 11 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2024 | 10226 | 0.050 |
Why?
| | Tracheostomy | 1 | 2024 | 121 | 0.050 |
Why?
| | Calcium, Dietary | 1 | 2023 | 56 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2007 | 640 | 0.050 |
Why?
| | Infant | 3 | 2024 | 9025 | 0.050 |
Why?
| | Reoperation | 1 | 2004 | 545 | 0.050 |
Why?
| | Signal Transduction | 1 | 2014 | 4925 | 0.050 |
Why?
| | Oximetry | 1 | 2021 | 87 | 0.040 |
Why?
| | Child, Preschool | 3 | 2024 | 10518 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4896 | 0.040 |
Why?
| | Hyperoxia | 1 | 2021 | 90 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 125 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 1877 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2021 | 263 | 0.040 |
Why?
| | Time Factors | 2 | 2024 | 6556 | 0.040 |
Why?
| | Homicide | 1 | 2019 | 60 | 0.040 |
Why?
| | World Health Organization | 1 | 2019 | 110 | 0.040 |
Why?
| | Databases, Factual | 1 | 2024 | 1269 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 7131 | 0.040 |
Why?
| | Terminal Care | 1 | 2022 | 237 | 0.040 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 205 | 0.040 |
Why?
| | Obesity | 2 | 2024 | 2882 | 0.040 |
Why?
| | Europe | 1 | 2019 | 364 | 0.040 |
Why?
| | Sex Distribution | 1 | 2019 | 359 | 0.040 |
Why?
| | Intracranial Hemorrhages | 1 | 2018 | 80 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2022 | 850 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 258 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2021 | 526 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1127 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1587 | 0.030 |
Why?
| | Child | 3 | 2024 | 20882 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 460 | 0.030 |
Why?
| | Decision Making | 1 | 2022 | 850 | 0.030 |
Why?
| | United States | 2 | 2024 | 13900 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2019 | 5762 | 0.030 |
Why?
| | Brain Ischemia | 1 | 2018 | 321 | 0.030 |
Why?
| | Hypoxia | 1 | 2021 | 1084 | 0.030 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 853 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2024 | 2483 | 0.030 |
Why?
| | England | 1 | 2012 | 72 | 0.020 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 105 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2012 | 83 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2070 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2012 | 189 | 0.020 |
Why?
| | Random Allocation | 1 | 2012 | 346 | 0.020 |
Why?
| | Medical Record Linkage | 1 | 2012 | 60 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5401 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2012 | 218 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2012 | 666 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5066 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1501 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 857 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 644 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 1001 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1201 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1698 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1214 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 428 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 400 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1547 | 0.020 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2007 | 48 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2406 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2008 | 648 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1205 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1086 | 0.020 |
Why?
| | Blood Vessels | 1 | 2007 | 187 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 485 | 0.020 |
Why?
| | Sirolimus | 1 | 2007 | 266 | 0.020 |
Why?
| | Recurrence | 1 | 2008 | 1007 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2009 | 1156 | 0.010 |
Why?
| | Preoperative Care | 1 | 2007 | 340 | 0.010 |
Why?
| | Age Factors | 1 | 2012 | 3144 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1274 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 3794 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5499 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1295 | 0.010 |
Why?
| | Risk Assessment | 1 | 2012 | 3240 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4063 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 964 | 0.010 |
Why?
| | Liver | 1 | 2007 | 1839 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 5420 | 0.010 |
Why?
| | Animals | 1 | 2012 | 35360 | 0.010 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|